Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platforms for the analysis and ...

Genomics company Illumina (NASDAQ:ILMN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales ...

Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

Illumina's (ILMN) stock slid 5% post-market after it released its Q4 earnings report and reiterated its 2025 guidance, ...

Roche, Illumina and Life Technologies ... in DNA libraries that can be used in high-throughput sequencing (Fig. 1b). Nextera technology can be used to create single- and dual-tagged libraries.

A Snakemake workflow for creating testing data for ecDNA analysis workflows: long reads (Nanopore with NanoSim) and short reads (Illumina with seqkit and mason).

Over the last six months, ANGLE has overcome technical issues to successfully use Illumina assays, coupled with their next generation sequencing (NGS) platform, to provide a complete solution for the ...

Over the last six months, Angle has overcome technical issues to successfully use Illumina assays, coupled with their next generation sequencing (NGS) platform, to provide a complete solution for the ...